Softomotive Raises $25m and Relocates to the UK as a Base for Global Growth in the Burgeoning RPA Market
Softomotive, a leader in Robotic Process Automation (RPA), today announced its Series A financing round of $25 million with Grafton Capital. This significant investment will help Softomotive build on its strong and growing position in the rapidly-expanding RPA market.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180927005832/en/
Softomotive raises $25m and relocates to the UK as a base for global growth in the burgeoning RPA market (Photo: Business Wire)
Grafton Capital is based in London and makes minority investments in rapidly growing, founder-owned software companies across Europe. Softomotive has selected London as it’s home city and recently moved to new offices.
The business world has woken up to the huge potential of RPA to improve performance by automating, repetitive, time-consuming tasks. Often, this need is generated by the existence of stand-alone legacy systems which are business-critical but expensive and difficult to replace. Interest has peaked as RPA is increasingly seen as a keystone of digitisation, which is top of most management agendas. According to P&S Market Research (May 2108), the RPA market is expected to reach $8.6 billion by 2023, growing at a CAGR of 36.2% during 2018-2023.
Softomotive, was one of the early pioneers of RPA with WinAutomation, and has since strengthened its market position with ProcessRobot, a leading enterprise RPA platform, including best-of-breed 3rd party AI tools. Together, these products, covering both attended (robots interacting with humans) and unattended (robots working independently) automation, provide enterprises of all sizes with the smoothest RPA journey by enabling them to start small, learn quickly and scale seamlessly.
“With this injection of growth capital and with London as its new base, Softomotive will expand its global footprint and accelerate the development of its product roadmap with a special emphasis on desktop automation and RPA for medium-sized enterprises,” said Marios Stavropoulos, CEO and Co-Founder of Softomotive. “We look forward to working with Grafton Capital as we enter our next growth phase.”
“Right from the start, Softomotive has proven to be a pioneer and innovator in the RPA marketplace,” added Argyris Kaninis, COO and Co-Founder of Softomotive. “With our unique portfolio comprising both desktop and server-based RPA software, we are well placed to serve enterprises of all sizes and this new partnership with Grafton Capital will help us achieve our future goals, including being a disruptive influence on the growing RPA market.”
Oliver Thomas, who led the investment for Grafton Capital and will join Softomotive’s Board of Directors commented: “We have spent the last months talking to industry leading enterprises in the US, Europe and Asia, all of whom have made rigorous assessments and selected Softomotive’s products ahead of other RPA leaders. It’s a great privilege to be working with founders who have built a world class product and have a clear vision as this exciting software category moves from early adoption to mass deployment.”
Softomotive is a leading worldwide provider of Robotic Process Automation solutions, trusted by more than 7,000 companies globally. Softomotive’s powerful Attended and Unattended RPA technology, from desktop installation to server based software, is quick to deploy, easy to use and provides best value for money.
About Grafton Capital
Headquartered in London, Grafton makes minority investments into rapidly growing, founder-owned software companies across Europe.
Chief Marketing Officer
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Incyte Announces Positive Interim Data from Phase 2 Trial of Pemigatinib, Its Selective FGFR Inhibitor, in Patients with Cholangiocarcinoma21.10.2018 10:45 | Pressemelding
Incyte Corporation (Nasdaq:INCY) announces updated data from its ongoing Phase 2 FIGHT-202 trial evaluating pemigatinib (INCB54828), its selective fibroblast growth factor receptor (FGFR) inhibitor, in patients with advanced/metastatic or surgically unresectable cholangiocarcinoma (bile duct cancer) who failed at least one previous treatment. In patients with FGFR2 translocations who were followed for at least eight months, interim study results demonstrated an overall response rate (ORR) of 40 percent, the primary endpoint, and a median progression free survival (PFS) of 9.2 months, a key secondary endpoint. These results are being presented at the European Society for Medical Oncology (ESMO) 2018 Congress in Munich, Germany in a poster presentation on Sunday, October 21 from 12:45 p.m. CEST to 1:45 p.m. CEST (6:45 a.m. ET to 7:45 a.m. ET). (Location: Hall A3 – Poster Area Networking Hub; Abstract #756P) “We are pleased to share updated interim results from our ongoing FIGHT-202 trial
Servier and Taiho Oncology Announce Phase III LONSURF® Study Has Met Primary and Secondary Endpoints Demonstrating Prolonged Overall Survival and Progression-Free Survival in Patients with Refractory Metastatic Gastric Cancer21.10.2018 09:10 | Pressemelding
Servier and Taiho Oncology, Inc. (U.S.), a subsidiary of Taiho Pharmaceutical Co., Ltd. (Japan), jointly announced today clinical data from the pivotal Phase III TAS-102 Gastric Study (TAGS) evaluating LONSURF® (trifluridine/tipiracil, TAS-102) versus placebo and best supportive care in patients with heavily pre-treated metastatic gastric cancer who have progressed or are intolerant to previous lines of therapy. The study met its primary endpoint of prolonged overall survival (OS) and secondary endpoint measures of progression-free survival (PFS) consistently supported the OS results, as well as continuing to demonstrate the predictable safety and tolerability profile of trifluridine/tipiracil. Data from TAGS was presented by Dr. Hendrik-Tobias Arkenau, Executive Medical Director of the Sarah Cannon Research Institute UK and an investigator for TAGS, at the ESMO 2018 Congress in Munich, Germany during an oral session (Abstract #LBA25). The study results were simultaneously published in
Phase 3 Data on Filgotinib in Biologic-Experienced Rheumatoid Arthritis to Be Presented at 2018 ACR/ARHP Annual Meeting20.10.2018 22:30 | Pressemelding
Gilead Sciences, Inc. (Nasdaq: GILD) and Galapagos NV (Euronext & NASDAQ: GLPG) today announced detailed results from the Phase 3 FINCH 2 clinical trial of filgotinib, an investigational, selective JAK1 inhibitor, in adults with moderately-to-severely active rheumatoid arthritis and prior inadequate response or intolerance to biologic agents. The data, which are being presented as a late-breaking poster at the 2018 American College of Rheumatology/Association of Rheumatology Health Professionals (ACR/ARHP) Annual Meeting in Chicago, suggest filgotinib has a potential role in addressing important unmet needs in the treatment of rheumatoid arthritis. Positive efficacy data from FINCH 2 were previously announced in September 2018. The data show statistically significant improvements in the proportion of patients achieving a range of clinical efficacy endpoints, including the proportion of patients achieving American College of Rheumatology 20 percent (ACR20, primary endpoint), 50 percent
Manchester United and True Religion Launch Denim Range19.10.2018 17:37 | Pressemelding
Manchester United (NYSE:MANU) and luxury denim brand True Religion have collaborated to launch a range of premium club branded denim wear. A first for the club, the new global partnership with the iconic American denim brand will see a range of men’s & women’s co-branded styles go on sale beginning 26th October in the club’s Megastore as well as online via United Direct and truereligion.com & eu.truereligion.com. The exclusive collection features jeans, shirts and jackets, including a highly desirable limited edition denim jacket embroidered with the club’s crest. Fans will have the opportunity to win a selection of clothing from the new range by visiting www.manutd.com/truereligion. Manchester United’s Group Managing Director, Richard Arnold, comments: “True Religion is a well-known, established name in fashion, creating unique designs without compromising on quality. The range we have collaborated on includes the same attention to detail and craftsmanship that has made True Religion
Arch Insurance Announces Strategic Leadership Changes19.10.2018 13:10 | Pressemelding
Arch Insurance today announced that Matt Shulman will assume the newly created role of CEO, Arch Insurance North America, effective January 1, 2019. In this role, he will lead Arch Insurance’s operations in the United States and Canada. He will report to Nicolas Papadopoulo, Chairman and CEO of Arch Worldwide Insurance Group. Mr. Shulman, who has more than 20 years of experience in the insurance industry, has been with Arch Insurance since 2009 and has served as the President and CEO of Arch Insurance Europe since 2016. “Matt brings significant U.S. and international experience to this role. Under his leadership, together with our senior team, Arch Insurance will continue to enhance our value proposition to our customers through a robust, diversified product portfolio, creative solutions and excellent service,” Mr. Papadopoulo said. Arch Insurance has also created a new organizational structure with three Chief Underwriting Officers (CUO) dedicated to specific lines of business. These
Takeda to Present Results from Phase 3 ALTA-1L Trial Highlighting Intracranial Efficacy of ALUNBRIG® (brigatinib) Versus Crizotinib in First-Line Advanced ALK+ Non-Small Cell Lung Cancer19.10.2018 12:00 | Pressemelding
Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that intracranial efficacy data from the Phase 3 ALTA-1L (ALK in Lung Cancer Trial of BrigAtinib in 1 st Line) trial showed improved intracranial progression-free survival (PFS) and intracranial objective response rate (ORR) with ALUNBRIG (brigatinib) compared to crizotinib among anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC) patients. Data for these secondary endpoints will be presented in a poster discussion at the European Society for Medical Oncology (ESMO) 2018 Congress on Friday, October 19 at 2:00 p.m. CET in Munich, Germany. These results further support ALUNBRIG as a potential treatment for adults with ALK+ locally advanced or metastatic NSCLC who had not received a prior ALK inhibitor. ALUNBRIG is currently not approved as first-line therapy for advanced ALK+ NSCLC. “ALK+ NSCLC often spreads to the brain, so having options that can clearly demonstrate efficacy both in the brain an